2. Characteristics of included trials (II).
| Study ID | Participants | Outcome measures | Sponsor | Country |
| Abu‐Mouch 2011 | Chronic hepatitis C genotype 1 | Sustained virological response | No information | Israel |
| Atsukawa 2016 | Chronic hepatitis C genotype 1 | Sustained virological response | No information | Japan |
| Barchetta 2016 | NAFLD | Liver steatosis, liver function | No | Italy |
| Behera 2018 | Chronic hepatitis C genotype 1, 4 | Sustained virological response | No | India |
| Boonyagard 2016 | NAFLD | Biochemical indices, HOMA, FibroScan measurement | No information | Thailand |
| Dabbaghmanesh 2018 | NAFLD | Biochemical indices | No | Iran |
| Esmat 2015 | Chronic hepatitis C genotype 4 | Sustained virological response | No information | Egypt |
| Foroughi 2016 | NAFLD | Liver steatosis, liver function | No | Iran |
| Geier 2018 | NAFLD (NASH) | Liver steatosis, liver function | Yes | Switzerland |
| Hosseini 2018 | NAFLD | Serum 25‐hydroxyvitamin D, adiponectin, HOMA‐IR, liver enzymes, and change in grade of NAFLD | No | Iran |
| Hussain 2019 | NAFLD | Body weight, BMI, insulin resistance, dyslipidaemia, hepatic enzymes, CRP, and adiponectin | No information | Pakistan |
| Jeong 2019 | Chronic hepatitis C genotype 1, 2, 3 | Sustained virological response | No information | Republic of Korea |
| Jha 2017 | Liver cirrhosis | Mortality | No information | India |
| Komolmit 2017a | Chronic hepatitis C | Serum levels of T‐helper cells associated cytokines | No | Thailand |
| Komolmit 2017b | Chronic hepatitis C | Serum fibrotic markers | No | Thailand |
| Lorvand Amiri 2016 | NAFLD | Liver function, body fat | No | Iran |
| Mobarhan 1984 | Liver cirrhosis | Bone mineral density | Yes | USA |
| Nimer 2012 | Chronic hepatitis C genotype 2 or 3 | Sustained virological response | No information | Israel |
| Pilz 2016 | Liver cirrhosis | Vitamin D status, liver function | No | Austria |
| Sakpal 2017 | NAFLD | Insulin resistance and serum ALT | No | India |
| Sharifi 2014 | NAFLD | Liver function, insulin resistance index | No | Iran |
| Shiomi 1999a | Liver cirrhosis | Bone mineral density | No information | Japan |
| Shiomi 1999b | Primary biliary cirrhosis | Bone mineral density | No information | Japan |
| Taghvaei 2018 | NAFLD | Biochemical indices, liver steatosis | No information | Iran |
| Vosoghinia 2016 | Chronic hepatitis C genotype 1, 2, 3, 4 | Early virological response | No | Iran |
| Xing 2013 | Liver transplant recipients | Acute cellular rejection rate | No | China |
| Yokoyama 2014 | Chronic hepatitis C genotype 1 | Sustained virological response | No information | Japan |
ALT: alanine aminotransferase BMI: body mass index CRP: C‐reactive protein HOMA‐IR: homeostatic model assessment for insulin resistance NAFLD: non‐alcoholic fatty liver disease NASH: non‐alcoholic steatohepatitis